T cell receptor (TCR) signaling in health and disease
Interaction of the T cell receptor (TCR) with an MHC-antigenic peptide complex results in
changes at the molecular and cellular levels in T cells. The outside environmental cues are …
changes at the molecular and cellular levels in T cells. The outside environmental cues are …
A review on nano-based drug delivery system for cancer chemoimmunotherapy
W Mu, Q Chu, Y Liu, N Zhang - Nano-Micro Letters, 2020 - Springer
Although notable progress has been made on novel cancer treatments, the overall survival
rate and therapeutic effects are still unsatisfactory for cancer patients …
rate and therapeutic effects are still unsatisfactory for cancer patients …
Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer
JR Cubillos-Ruiz, SE Bettigole, LH Glimcher - Cell, 2017 - cell.com
Malignant cells utilize diverse strategies that enable them to thrive under adverse conditions
while simultaneously inhibiting the development of anti-tumor immune responses. Hostile …
while simultaneously inhibiting the development of anti-tumor immune responses. Hostile …
Clinical use of dendritic cells for cancer therapy
Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …
Cancer immunotherapy via dendritic cells
K Palucka, J Banchereau - Nature Reviews Cancer, 2012 - nature.com
Cancer immunotherapy attempts to harness the power and specificity of the immune system
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …
[HTML][HTML] Classification of current anticancer immunotherapies
During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …
Dendritic-cell-based therapeutic cancer vaccines
K Palucka, J Banchereau - Immunity, 2013 - cell.com
The past decade has seen tremendous developments in novel cancer therapies through the
targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and …
targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and …
Dendritic cell–based immunotherapy: state of the art and beyond
KF Bol, G Schreibelt, WR Gerritsen, IJM De Vries… - Clinical cancer …, 2016 - AACR
Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …
antitumor immune response against tumor antigens and was first explored in a clinical trial …
Tumor infiltrating lymphocytes in ovarian cancer
PP Santoiemma, DJ Powell Jr - Cancer biology & therapy, 2015 - Taylor & Francis
The accumulation of tumor infiltrating lymphocytes (TILs) in ovarian cancer is prognostic for
increased survival while increases in immunosuppressive regulatory T-cells (Tregs) are …
increased survival while increases in immunosuppressive regulatory T-cells (Tregs) are …
Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine
GN Shi, CN Zhang, R Xu, JF Niu, HJ Song, XY Zhang… - Biomaterials, 2017 - Elsevier
Whole tumor cell lysates (TCL) have been implemented as tumor antigens for cancer
vaccine development, although clinical outcomes of TCL-based antitumor immunotherapy …
vaccine development, although clinical outcomes of TCL-based antitumor immunotherapy …